Lantus

Insulin glargine

Treatment of DM in adults, adolescents & childn ≥2 yr.

SC Individualised dosage. Inject once daily at the same time each day.

Hypersensitivity.

Not for diabetic ketoacidosis. Perform continuous rotation of inj site to reduce risk of developing lipodystrophy & cutaneous amyloidosis. Monitor blood glucose after the change in inj site; dose adjustment of antidiabetic medications may be considered. Caution when transferring to another type or brand of insulin. Early morning hypoglycaemia can be expected. Caution in patients in whom hypoglycaemic episodes might be of clinical relevance (eg, patients w/ significant stenoses of the coronary arteries or of the blood vessels supplying the brain as well as in patients w/ proliferative retinopathy, particularly if not treated w/ photocoagulation; patients w/ diminished warning symptoms of hypoglycaemia (eg, patients in whom glycaemic control is markedly improved, in whom hypoglycaemia develops gradually, elderly, after transfer from animal to human insulin, in whom an autonomic neuropathy is present, w/ a long history of DM, suffering from a psychiatric illness, receiving concurrent certain medications). Closely monitor patients & adjust dose, if necessary, in case of factors that increase susceptibility to hypoglycaemia eg, change in inj area; improved insulin sensitivity (eg, by removal of stress factors); unaccustomed, increased or prolonged physical activity; intercurrent illness (eg, vomiting, diarrhoea); inadequate food intake; missed meals; alcohol consumption; certain uncompensated endocrine disorders (eg, in hypothyroidism & in anterior pituitary or adrenocortical insufficiency); concomitant use w/ certain other medicines. Intercurrent illness requires intensified metabolic monitoring. May cause insulin Abs to form. Reports of cardiac failure w/ pioglitazone, especially in patients w/ risk factors for development of cardiac heart failure. May impair ability to drive & use machines. Patients w/ renal or hepatic impairment. Pregnancy & lactation. Childn <2 yr. Elderly ≥65 yr.

Hypoglycaemia. Lipohypertrophy; inj site reactions.

Enhanced blood-glucose-lowering effect & increased susceptibility to hypoglycaemia w/ oral antidiabetics, ACE-inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamide antibiotics. Reduced blood-glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. Potentiated or weakened blood-glucose-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Risk of hypoglycaemia, which may sometimes be followed by hyperglycaemia w/ pentamidine. Reduced or absent signs of adrenergic counter-regulation w/ sympatholytic medicinal products (eg, β-blockers, clonidine, guanethidine & reserpine).

Insulin Preparations

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

P₁